Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide (Q38300138)

1 September 2017

title

Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide (English)

1 reference

1 September 2017

0 references

multiple drug resistance

1 reference

1 reference

Elai Davicioni

1 reference

1 September 2017

C Patrick Reynolds

1 reference

1 September 2017

Nino Keshelava

1 reference

1 September 2017

Zesheng Wan

1 reference

1 September 2017

Lingyun Ji

1 reference

1 September 2017

Richard Sposto

1 reference

1 September 2017

Timothy J Triche

1 reference

1 September 2017

language of work or name

English

0 references

publication date

10 July 2007

1 reference

Journal of the National Cancer Institute

1 September 2017

published in

1 reference

1 September 2017

1 reference

1 September 2017

1 reference

1 September 2017

page(s)

1107-1119

1 reference

Common solid tumors of childhood

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Profiling and functional annotation of mRNA gene expression in pediatric rhabdomyosarcoma and Ewing's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Gene expression profiling of pediatric acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

cDNA microarray analysis of changes in gene expression induced by neuronal hypoxia in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Global gene expression in human myocardium-oligonucleotide microarray analysis of regional diversity and transcriptional regulation in heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

A histone deacetylase inhibitor potentiates retinoid receptor action in embryonal carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Short tandem repeat profiling provides an international reference standard for human cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Role of Class I and Class II histone deacetylases in carcinoma cells using siRNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Overexpression of histone deacetylase 1 confers resistance to sodium butyrate-mediated apoptosis in melanoma cells through a p53-mediated pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Analysis of the glutathione S-transferase (GST) gene family

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Mechanisms of the copper-dependent turnover of the copper chaperone for superoxide dismutase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

p18 Ink4c and Pten constrain a positive regulatory loop between cell growth and cell cycle control

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Overexpression of TAP/p15 heterodimers bypasses nuclear retention and stimulates nuclear mRNA export

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Core promoter binding by histone-like TAF complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Effects of the histone deacetylase inhibitor valproic acid on Notch signalling in human neuroblastoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Favorable neuroblastoma genes and molecular therapeutics of neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Histone Deacetylases: Unique Players in Shaping the Epigenetic Histone Code

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Cell-cycle regulation of the DNA topoisomerase IIalpha promoter is mediated by proximal CCAAT boxes: possible involvement of acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Effects of X-irradiation and sodium butyrate on cell-cycle traverse on normal and radiosensitive lymphoblastoid cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Modulation of radiation response by histone deacetylase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Cell cycle checkpoint signaling involved in histone deacetylase inhibition and radiation-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM044

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJM044

1 reference

1 September 2017

1 reference